TRKA Expression in Neuroblastoma
Author Information
Author(s): V Combaret, N Gross, C Lasset, K Balmas, R Bouvier, D Frappaz, C Beretta-Brognara, T Philip, MC Favrot, J-L Coil
Hypothesis
Does TRKA expression correlate with clinical outcomes in neuroblastoma?
Conclusion
TRKA expression is a strong prognostic factor in neuroblastoma, particularly when combined with N-MYC or CD44 assessment.
Supporting Evidence
- 74 out of 108 neuroblastomas expressed TRKA protein, correlating with favorable clinical outcomes.
- Event-free survival at 3 years was 81% in TRKA-positive patients compared to 27% in TRKA-negative patients.
- TRKA expression was significantly associated with low stage and absence of N-MYC amplification.
Takeaway
This study found that a protein called TRKA can help doctors predict how well children with neuroblastoma will do, especially when looking at other factors like N-MYC and CD44.
Methodology
TRKA expression was evaluated on 122 untreated neuroblastomas using immunohistochemistry, and the prognostic value was analyzed through univariate and multivariate analyses.
Potential Biases
Selection of patients was based on the availability of sufficient tumor tissue, which may introduce bias.
Limitations
The study's sample included a disproportionate occurrence of low stage neuroblastomas, which may affect the generalizability of the results.
Participant Demographics
Patients were untreated children diagnosed with neuroblastoma, with a mean follow-up time of 35 months.
Statistical Information
P-Value
4 x 10-5
Confidence Interval
[0;35]
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website